Bayer to present new data at ASCO 2019 highlighting commitment to evolve cancer treatment paradigm (for specialized target groups only)

Data from Bayer’s growing oncology portfolio include new analyses on the company’s precision oncology treatment larotrectinib, with two oral presentations in patients with solid tumors that harbor an NTRK gene fusion: one on expanded data in pediatric patients and the other one in patients with brain metastases or primary central nervous system tumors / First detailed presentation of quality of life data from the Phase III ARAMIS trial of the investigational androgen receptor antagonist darolutamide in patients with non-metastatic castration-resistant prostate cancer / Oral presentation on investigational ATR inhibitor BAY 1895344 in patients with advanced solid tumors / Long-term data from patients with relapsed or refractory follicular lymphoma treated with copanlisib
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news